home / stock / lian / lian news

LIAN News and Press, LianBio From 06/06/23

Stock Information
Company Name: LianBio
Stock Symbol: LIAN
Market: NASDAQ
Menu
LIAN LIAN Quote LIAN Short LIAN News LIAN Articles LIAN Message Board
Get LIAN Alerts

News, Short Squeeze, Breakout and More Instantly...
LIAN - SFIX, WGS and ZUMZ are among after hour movers

2023-06-06 17:21:13 ET Gainers: GeneDx Holdings ( WGS ) +6% . Zumiez ( ZUMZ ) +6% . Stitch Fix ( SFIX ) +6% . LianBio ( LIAN ) +5% . Dave & Buster's Entertainment ( PLAY ) +5% . Losers: Couchbase ( BASE ) -17% ...
LIAN - LianBio Announces Topline Results from Phase 2a Proof of Concept Trial Evaluating Infigratinib in Patients with Gastric Cancer & Receipt of Breakthrough Therapy Designation in China

SHANGHAI, China and PRINCETON, N.J., June 06, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced positive topline results from a Phase 2a proof of concept trial eva...

LIAN - LianBio to Participate in Upcoming Investor Conferences

SHANGHAI, China and PRINCETON, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that members of the management team will participate in the followi...

LIAN - Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC

2023-05-14 14:20:00 ET Summary Bliss Biopharma (Hangzhou) announced it may out-license global rights (ex-China) for its HER2 ADC to Japan’s Eisai Pharma in a deal with a potential value of $2 billion. Shanghai Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to...
LIAN - LianBio GAAP EPS of -$0.22 beats by $0.05

2023-05-12 07:01:07 ET LianBio press release ( NASDAQ: LIAN ): Q1 GAAP EPS of -$0.22 beats by $0.05 . Cash, cash equivalents, marketable securities and restricted cash at March 31, 2023 totaled $286.6 million compared to $302.4 million as of December 31, 2022...

LIAN - LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update

Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpoint China National Medical Products Administration ( NMPA) accepted mavacamten New Drug Application (NDA) with priority review Mavacamten commer...

LIAN - LianBio gets approval for heart drug Camzyos in Macau

2023-05-11 08:06:38 ET LianBio ( NASDAQ: LIAN ) said Pharmaceutical Administration Bureau of the Macau approved Camzyos (mavacamten) to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in the Macau Special Administrative Region (SAR) of China "...
LIAN - LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special Administrative Region (SAR) of China

SHANGHAI, China and PRINCETON, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that CAMZYOS ® (mavacamten) has received marketing app...

LIAN - Scilex, Cytek top healthcare gainers; ZyVersa, Baudax among losers

2023-04-26 10:09:11 ET Gainers: Scilex Holding ( SCLX ) +14% . Cytek Biosciences ( CTKB ) +12% . Minerva Neurosciences ( NERV ) +10% . Vincerx Pharma ( VINC ) +9% . LianBio ( LIAN ) +7% . Losers: ZyVersa Therapeutics ( Z...

LIAN - Bristol Myers, LianBio's heart drug Camzyos meets main goal in Chinese patients study

2023-04-26 08:53:02 ET Bristol Myers Squibb ( NYSE: BMY ) and LianBio's ( NASDAQ: LIAN ) drug Camzyos (mavacamten) met the main goal of a phase 3 trial in Chinese patients with a type of heart disease. LianBio was evaluating mavacamten in the study, dubbed EXPLORE...
Previous 10 Next 10